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Abstract
The phenotype of many regulatory circuits in which mutations can cause complex, polygenic diseases is
to some extent robust to DNA mutations that affect circuit components. Here I demonstrate how such
mutational robustness can prevent the discovery of genetic disease determinants. To make my case, I use
a mathematical model of the insulin signaling pathway implicated in type 2 diabetes, whose signaling
output is governed by 15 genetically determined parameters. Using multiple complementary measures of
a parameter’s importance for this phenotype, I show that any one disease determinant that is crucial in
one genetic background will be virtually irrelevant in other backgrounds. In an evolving population that
drifts through the parameter space of this or other robust circuits through DNA mutations, the genetic
changes that can cause disease will vary randomly over time. I call this phenomenon causal drift. It means
that mutations causing disease in one (human or non-human) population may have no effect in another
population, and vice versa. Causal drift casts doubt on our ability to infer the molecular mechanisms of
complex diseases from non-human model organisms.
Manuscript
Click here to download Manuscript: InsulinSignaling_PLoS_ONE_revised_main.pdf 
2Introduction
Complex genetic diseases like type 2 diabetes, Crohn’s disease, and schizophrenia are influenced by
multiple genes whose identification is a great challenge for genomics [1–5]. Aside from environmental
influences, complex gene interactions that affect disease risk are among the biggest obstacles to understand
the causes of such complex diseases [6–11]. For example, genome-wide association studies of healthy and
diseased individuals can often explain only little disease risk when they add the effect of many single
nucleotide changes observed in diseased individuals [1, 5–7]. The causes of this phenomenon, which is
also known as the ‘missing heritability’ problem, include the influence of rare mutations, many variants
with weak effects, gene copy number changes, epigenetic changes, parent-of-origin effects, but especially
non-additive or epistatic interactions among genetic polymorphisms at different loci [6, 8–13].
Genome-wide association studies can provide statistical evidence for a gene’s role in disease, but they
do not resolve the mechanistic causes of disease. Progress in understanding these causes usually involves
the analysis of regulatory or signaling circuits, in which molecular interactions among circuit components
have been characterized. Examples include the potential role of insulin signaling in type II diabetes, or
that of the mitogen activated protein kinase (MAPK) signaling circuit in hypertension [14–17]. Such
circuits are complex and their analysis requires quantitative mathematical models. Most such models
represent a circuit’s dynamics through ordinary differential equations whose state variables describe
how the concentration or activity of circuit molecules, especially proteins, changes over time through
interactions with other molecules. The strengths of these interactions are genetically encoded, for example
in the amino acid sequences of protein interaction partners, and encapsulated in one or more model
parameters. A circuit operating inside a cell usually receives an external signal, such as an insulin pulse
in response to ingested sugar, and its response regulates downstream molecules such as transporters that
can import glucose [14,15]. Genetic change can alter the parameters that influence a circuit’s behavior,
and in doing so, can change the circuit’s phenotype in a manner that leads to disease.
Understanding the phenotype of any one complex circuit is hindered by the usually unknown (and
difficult to measure) values of most of its parameters, which may number in the dozens to hundreds [18].
The time-honored strategy of fitting the parameters to experimental phenotypic data has a serious
limitation: Myriad sets of parameters can usually reproduce the same experimentally measured phenotype.
Recent work therefore increasingly focuses on characterizing a model’s entire parameter space. This is done
by sampling the usually high-dimensional space, allowing each parameter to vary over some biologically
sensible range. The subset of viable parameters, i.e., parameter sets yielding a given phenotype, can have
many dimensions and a complex geometry [19–28].
Because a circuit’s parameters are genetically determined, the size of the viable parameter set also
reflects the amount of genetic change a circuit can tolerate while preserving its phenotype, that is,
the circuit’s robustness to mutations [19–21, 29, 30]. Such robustness is a property of many biological
systems [31]. But while circuits are to some extent robust, they are not equally robust to all genetic
perturbations. Their phenotypes are much more sensitive to changes in some parameters than in others, a
phenomenon that has been called ‘sloppy control’ [22, 32–35]. Especially important parameters could thus
in principle serve as ‘choke points’ to help steer a circuit from a diseased to a normal state as part of a
therapeutic intervention [36].
I here show that mutational robustness can impair our ability to detect genetic disease determinants.
This is trivially true for systems with sloppy control: Genetically encoded parameters that do not affect a
phenotype when altered through DNA mutations will be invisible in a genome-wide association study. But
in genetically heterogenous populations the problem can be much worse. To make my case I use the insulin
signaling circuit as a representative of many other, similarly robust circuits [22,32]. The insulin circuit has
been implicated in type II diabetes, a complex genetic disease and serious public health risk [14,37,38].
Disease manifestations include cellular resistance to pancreas- produced insulin, which reduces the rate at
which cells import glucose and thus remove glucose from the bloodstream. The resulting hyperglycemia
and has debilitating long-term effects such as blindness. The insulin signaling circuit, a small part of a
3highly complex glucose homeostasis system [38], responds to the presence of insulin at the cell surface and
triggers the uptake of glucose into muscle cells and adipocytes. Naturally occurring mutations in circuit
genes affect insulin resistance and diabetes risk [39–44]. Starting from a tractable yet experimentally
validated mathematical model of this robust circuit [15], I sample its high-dimensional parameter space
and study the effects of individual disease determinants (parameters) on its glucose uptake phenotype.
Doing so for many different genetic backgrounds (different viable parameter sets) reveals that any one
disease determinant that is crucial in one background will be modestly important in another and virtually
irrelevant in yet another background. In an evolving population that explores the parameter space of such
a circuit through DNA mutations, genetic determinants of disease can vary randomly over time. I call
this phenomenon causal drift.
Methods
My starting point is a widely used experimentally validated ordinary differential equation model of the core
insulin signaling pathway [15]. To render parameter space sampling tractable I simplified this model without
sacrificing its dynamical features, considering only events downstream of the insulin-receptor interaction.
Briefly, the simplified model captures the following events and processes (Figure 1a). Insulin-bound
insulin-receptor interacts with IRS1 (insulin receptor substrate 1), which becomes tyrosine-phosphorylated.
Phosphorylated IRS1 (denoted as IRS1P in the model) helps activate phosphoinositide 3-kinase (PI3K),
which phosphorylates phosphatidylinositol (4,5)-bisphosphate (PI45P2) to produce the second messenger
phosphatidylinositol (3,4,5)-triphosphate (PI345P2). Unless the latter molecule is dephosphorylated
by the phosphatase PTEN (phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase) to PI45P2, or by
the phosphatase SHIP (SH2 domain-containing inositol 5’-phosphatase)) to phosphatidylinositol (3,4)-
bisphosphate (PI34P2), it binds to a number of effector molecules, among them the protein kinase Akt
(also known as protein kinase B), and protein kinase C-ζ (PKCZ). In response, both molecules become
phosphorylated (AktP and PKCZP in the model), and contribute to the translocation of the glucose
transporter GLUT4 from intracellular compartments (GLUT4int) to the plasma membrane (GLUT4mem),
which enables the cell to import glucose. AktP also exerts positive feedback on insulin signaling, by
inhibiting the ability of PTP1B (phospho-tyrosine protein phosphatase 1B) to dephosphorylate IRS1P
and the insulin receptor [45]. Moreover, PKCZP exerts negative feedback by phosphorylating serine
residues on IRS1, which can reduce the concentration of IRS1P , and thus the activation of PI3K [46].
Model structure. Each of the state variables of the model’s 14 ordinary differential equations
represents the amount or proportions of a molecule through square brackets enclosing molecule abbre-
viations from the preceding paragraph. Amounts are given in nanomoles (nM) for compounds IRS1,
IRS1P ,IRS1SP , PI3K, and for the complex of the latter two, denoted as IRS1P.PI3K. All other state
variables are given in percentages, such that the following sums are equal to 100 percent: Akt+AktP ,
PKCZ + PKCZP , GLUT4int+GLUT4mem. Rate parameters for mass-action reactions are written in
lowercase k, subscripted with F and B for forward and backward reaction rates, respectively. Those
parameters that are subject to parameter space sampling are written in bold type.
The model’s first three equations are
4d[IRS1]
dt
= −kF,IRS1P[IRS1][SIGNAL] + fAktPkB,IRS1P[Akt][IRS1P ] (1)
+ kB,IRS1SP[IRS1SP ]− fPKCZP[PKCZP ][IRS1]
d[IRS1P ]
dt
= kF,IRS1P[IRS1][SIGNAL]− fAktPkB,IRS1P[Akt][IRS1P ] (2)
+ kB,IRS1P.PI3K[IRS1P.PI3K]− kF,IRS1P.PI3K[PI3K][IRS1P ]
d[IRS1SP ]
dt
= fPKCZP[PKCZP ][IRS1]− kB,IRS1SP[IRS1SP ] (3)
These equations incorporate the action of insulin on changes in the concentration of IRS1. The
SIGNAL term corresponds to the concentration of insulin receptors singly or doubly phosphorylated in
response to insulin, which is the upstream input for the model considered here (and is equivalent to the
sum of state variables x4 +x5 in [15]). The left-most terms on the right-hand sides of equations (1) and (2)
reflect the increase in tyrosine-phosphorylated IRS1, i.e., of IRS1P , as a result of this signal. The second
terms reflect the positive feedback of AktP on the production of IRS1P . This feedback is mediated
by PTP1B, which is not directly modeled here, but through a dimensionless feedback parameter fAkt
which reflects the feedback strength. The terms corresponding to this feedback are simple mass action
terms. Note that this feedback is expressed as an increase in IRS1, and although Akt and not AktP
appears in the pertinent expressions, AktP = 100−Akt, implying that IRS1P will show an increase that
is proportional to AktP .
The two major terms on the right-hand side of equation (3) reflect the creation of serine-phosphorylated
IRS1, i.e., IRS1SP , by PKCZP , whose rate is modeled by the dimensionless feedback parameter fPKCZP ,
and to the conversion of IRS1SP into IRS1. These terms are matched by the third and fourth right-hand
terms of equation (1).
Equations 4 and 5 below reflect the association and dissociation of IRS1P , the active IRS1 moiety in
this model, with PI3K in the complex IRS1P.PI3K.
d[PI3K]
dt
= kB,IRS1P.PI3K[IRS1P.PI3K] (4)
− kF,IRS1P.PI3K[PI3K][IRS1P ]
d[PI3K.IRS1P ]
dt
= kF,IRS1P.PI3K[PI3K][IRS1P ] (5)
− kB,IRS1P.PI3K[IRS1P.PI3K]
The following equations (6), (7), and (8) encapsulate the creation of PI345P3 from PI45P2, and
its decay into PI45P2 or PI34P2. Although the dephosphorylation of PI345P3 is promoted by the
phosphatase PTEN , the concentration of this phosphatase is not modeled directly here. Its action
is instead encapsulated in the parameter kB,PI45P2. Likewise, the action of the phosphatase SHIP to
promote the decay of PI345P3 to PI34P2 is encapsulated in kB,PI34P2. Note that these three equations
obey mass balance, such that the sum of the relative amounts of the three phospholipids is constant.
5d[PI345P3]
dt
= kF,PI45P2[IRS1P.PI3K][PI45P2] + kF,PI34P2[PI34P2] (6)
− (kB,PI45P2 + kB,PI34P2)[PI345P3]
d[PI45P2]
dt
= kB,PI45P2[PI345P3]− kF,PI45P2[IRS1P.PI3K][PI45P2] (7)
d[PI34P2]
dt
= kB,PI34P2[PI345P3]− kF,PI34P2[PI34P2] (8)
Equations (9)-(12) describe the phosphorylation (stimulated by PI345P3) and dephosphorylation of
the proteins Akt (9-10) and PKCZ (11-12).
d[Akt]
dt
= kB,AktP[AktP ]− kF,AktP[PI345P3][Akt] (9)
d[AktP ]
dt
= kF,AktP[PI345P3][Akt]− kB,AktP[AktP ] (10)
d[PKCZ]
dt
= kB,PKCZP[PKCZP ]− kF,PKCZP[PI345P3][PKCZ] (11)
d[PKCZP ]
dt
= kF,PKCZP[PI345P3][PKCZ]− kB,PKCZ[PKCZP ] (12)
Both AktP and PKCZP promote the translocation of glucose transporters from the cell’s interior
(GLUT4int) to the membrane (GLUT4mem). I here follow [15], which assumes that receptors are
translocated to the membrane at a basal (non-insulin-stimulated) rate determined by a parameter k13 [15],
and internalized at a different basal rate (k−13), such that in the absence of insulin stimulation, only
four percent of receptors are membrane-localized. Insulin-stimulated translocation to the cell membrane
proceeds at a rate k13′ chosen such that at maximum stimulation 10 times more receptors (40 percent)
are membrane-localized than in the unstimulated state. Receptors are synthesized and decay at rates k14
and k−14. The resulting equations (using the parameter names from [15]) are
d[GLUT4int]
dt
= k−13[GLUT4mem]− (k13 + k13′)[GLUT4int]
+ k14 − k−14[GLUT4int] (13)
d[GLUT4mem]
dt
= (k13 + k13′)[GLUT4int]− k−13[GLUT4mem] (14)
Because k13′ is a parameter that reflects insulin stimulation, it must depend on the concentrations of AktP
and PKCZP . This dependency is given by k13′ = [(40/60)−(4/96)]k−13(0.2[PKCZP ]+0.8[AktP ])/APeq,
where APeq is equal to [AktP ] + [PKCZP ] at maximal insulin stimulation. See [15] for further details on
this expression. In my analysis, I did not vary the parameters in (13) and (14) but used only their published
values, which are k13 = 0.006958min
−1, k−13 = 0.167min−1, k14 = 0.11088min−1, k−14 = 0.001155min−1,
APeq = 9.09% [15].
Together, equations (1)-(12) form the core model I analyze. That is, I subject all their parameters to
parameter space sampling. Equations (13) and (14) link this core to the pathway output, namely the
concentration of membrane-localized glucose transporter, which determines the glucose uptake rate.
The molecular components of this model are of demonstrable relevance to type 2 diabetes [47]. For
example, IRS1 tyrosine phosphorylation and its interaction with PI3K is impaired in skeletal muscle of
type 2 diabetes patients [47,48]. Activation of PKCZ by PI345P3 is impaired in muscle tissues of type 2
diabetes patients [47,49]. And while GLUT4 concentrations are not necessarily altered in type 2 diabetes,
GLUT4 translocation is impaired [50].
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of insulin signaling [16,37,47,51–53]. (Every one of these complexities would further increase the potential
for causal drift, as it would add additional parameters that can vary without causing the phenotype to
vary.) First, the model does not represent some molecular interactions explicitly, such as that between
AktP and PTPB [45], but encapsulates them in a parameter. Second, it ignores the indirect nature
of some interactions, such as that between PI3K and Akt, which is mediated by mTOR (mammalian
target of rapamycin), or that between AktP and GLUT4 translocation, which is mediated by proteins
AS160 and RabGTPase [47, 54] – it represents the latter through phenomenological terms in (13) and
(14). Third, the model does not explicitly represent the multiple phosphorylation sites on IRS1 (see
[Fig. 4] of [47] and [55]). Fourth, it neglects some pathway components, such as IRS2 [56]. Fifth, it
does not incorporate cross-talk to other important signaling pathways, such as the Erk (extracellular
signal-related kinase) pathway [16, 57]. Sixth, on a higher level of organization, the model does not
represent interactions between different organs relevant for glucose homeostasis, such as that between the
brain and pancreas [38]. Seventh, the model does not consider aspects of glucose homeostasis different
from glucose uptake, e.g., the regulated synthesis of glycogen, which is also mediated by Akt and one
of its targets, glycogen synthase kinase 3 [58]. Finally, the model does not incorporate possible gene
expression changes of signaling proteins. More detailed models may give a more comprehensive view
of insulin signaling [14, 16, 51–53]. However, their complexity (e.g., more than 100 parameters in [16])
makes parameter space sampling impossible, because the computational cost of such sampling increases
exponentially with the number of parameters [23].
Input signal, initial states, and parameter values. The upstream signal that serves as the model
input is the concentration of insulin-bound insulin receptor in response to a (rectangular) pulse of 100 nM
insulin that lasts from t = 0 to t = 15min. This response, encapsulated in the variable SIGNAL is shown
in Figure 1b. It shows a sharp increase of insulin-bound receptor from a value of zero to a value close to
0.9nM in less than a minute after insulin exposure, followed by a 15 minute plateau and a fast decay after
insulin removal at 15mins. Although I used this specific insulin input primarily to ensure consistency
and comparability with the previous model [15], I note that its time scale of insulin administration and
response are consistent with experimental work [14,59].
The initial values of other state variables at time t = 0 reflect the assumption that before insulin
stimulation, (i) the concentration of active, phosphorylated IRS1 is negligible ([IRS1](0) = 1nM,
[IRS1P ](0) = 0nM, [IRS1SP ](0) = 0nM) [60, 61], (ii) the concentration of the active PI3K-IRS1P
complex is zero ([PI3K](0) = 0.1nM, [IRS1P.PI3K](0) = 0nM) [62,63], (iii) most of the relevant signaling
phospholipids exist in the form of PI45P2 ([PI345P3] = 0.31%, [PI45P2] = 99.4%, [PI34P2](0) = 0.29%)
[64], (iv) all of Akt and PKCZ exist in their inactive forms ([Akt](0) = 100%, [AktP ](0) = 0%,
[PKCZ](0) = 100%, [PKCZP ](0) = 0%), and (iv) the vast majority of glucose transporters GLUT4
exists in the inactive, intracellular form ([GLUT4int](0) = 96%, [GLUT4mem](0) = 4%) [65, 66]. Because
absolute molecular concentrations given by [15] (≈ 10−15M) are some three orders of magnitude too low
given today’s knowledge about eukaryotic cell volumes [67–70], I rescaled these concentrations by a factor
1000, and rescaled parameters depending on concentrations [15] accordingly: kF,IRS1P = 10min
−1nM−1,
kB,IRS1P = 5min
−1, kB,IRS1SP = 0.1min−1, kF,IRS1P.PI3K = 0.706min−1nM−1, kB,IRS1P.PI3K =
10min−1, kF,PI45P2 = 300min−1nM−1 , kB,PI45P2 = 42.15min−1, kF,PI34P2 = 2.96min−1, kB,PI34P2 =
2.77min−1, kF,AktP = kF,PKCZP = 0.21min−1, kB,AktP = kB,PKCZP = 6.93min−1, fAktP = 0.001,
fPKCZP = 0.3. With these parameter values, the simplified signaling model I use can reproduce the state
variables’ temporal dynamics from [15], some of which have been experimentally validated.
Parameter space sampling. Only some of the values of the 15 biochemical parameters I subject
to sampling (bold type in (1)-(12)) have been measured [15]. Because the model’s parameter values
span approximately six orders of magnitude, i.e., the interval (10−3, 103) [15], I allowed each of the 15
parameters to assume values within this interval. I sampled in the logarithmic domain, i.e., I created
uniformly distributed random variates x ∈ (−3, 3), and set the corresponding parameter to 10x. I refer to
7each sampled (15-dimensional) point as a parameter set or a parameter vector. I estimated sensitivity
coefficients S (equation (16)) by imposing a ten percent change in the value of a focal parameter p and
computing the resulting effect on the glucose uptake rate U (defined below in equation (15)).
Signaling output. The output of the modeled pathway is the concentration of membrane-bound
glucose transporter GLUT4mem, because it is proportional to the glucose a cell can import per unit time.
This concentration – and thus the rate of glucose uptake – vary over time as a function of changes in
other state variables. As a proxy for the total glucose uptake U within a one hour time interval after
insulin exposure I compute the integral
U =
∫ 60
0
[GLUT4mem](t)dt (15)
which is also the molecular phenotype I consider. For the parameter values given above, Uref ≈
1.17 × 103 arbitrary units (a.u.), which I use as a reference for a normal (healthy, wild-type) glucose
uptake phenotype. To define a phenotype associated with disease, I took advantage of the experimental
observation that insulin-resistant mice with impaired GLUT4 expression show an approximately 70 percent
reduction in glucose uptake by adipocytes at a concentration of 100nM insulin, i.e., from ≈ 85± 35(s.dev.)
to ≈ 25± 12 attomoles per cell per minute [59]. I translated these figures into the arbitrary units above,
allowing one standard deviation below Uref as the minimally admissible glucose uptake for the normal
state, and one standard deviation above 30% of Uref as the maximally admissible glucose uptake rate
for the diseased state. This yields Unormal := U+ > 691.26 and Udiseased := U− < 502.86. In addition, I
required for a normal phenotype that GLUT4mem shows bona fide regulation in response to insulin, i.e.,
after increasing when stimulated with insulin, it needed to decrease upon insulin-removal. Specifically,
after [GLUT4mem] had reached a maximum at some time point tmax ∈ (0, 60), I required that it falls
below one half of this maximum for some t ∈ (tmax, 60).
Creation of polymorphic ‘populations’. To create groups of parameter sets (‘populations’) that
are not uniformly sampled but derived from and localized near some point ~pinit in parameter space, I
used the following procedure. Starting from ~pinit (which was itself taken from a uniform sample of viable
parameters), I chose one of the 15 parameters in it at random, and altered this parameter by replacing it
with a random variate 10x, where x was a uniformly distributed pseudorandom number in the interval
(−3, 3). In other words, I randomized the value of this parameter. If the resulting new parameter set
yielded normal glucose uptake, I retained it. If not, I chose again a random parameter among the 15
parameters in ~pinit and randomized it in the same way. I repeated this procedure until I had found a new
parameter set ~p′ with normal glucose uptake. I then repeated this randomization procedure starting from
~p′ instead of ~pinit , until I had found another parameter set ~p′′ with normal glucose phenotype (in which
now at most two parameters are altered relative to ~pinit). I repeated this procedure starting from ~p
′′ and
its ‘descendants’ until I had identified a total of 10 viable parameter sets increasingly distant to ~pinit in
parameter space, but all showing normal glucose uptake. After that, I restarted the procedure from ~pinit,
until I had created another 10 parameter sets in the same manner, and so on, until I had created 100 such
10-tuples of parameter sets, i.e., a ‘population’ of 1000 related parameter sets.
With such a population in place, I derived from it another set of 1000 parameter points whose members
all had pathologically reduced glucose uptake (U < U−). I did so with the following procedure. First, I
chose at random a member (parameter set) of the population with normal glucose uptake, and from this
parameter set I chose at random one of the 15 parameters. Second, I mutated (randomized) the chosen
parameter. Third, I computed whether the population member with the mutated parameter has a glucose
uptake phenotype below the disease threshold (U < U−). If so, I kept the mutated population member. I
repeated these steps (choosing population members and parameters with replacement) until I had created
a population of 1000 individuals. Each of its members has a pathologically reduced glucose uptake, and
each is derived from a single individual of the population with normal glucose uptake through mutation of
a single, randomly chosen parameter.
8For logistic regression, I encoded the glucose uptake phenotype in a binary manner, assigning a value
of one and zero to parameter sets associated with a healthy and diseased glucose uptake phenotype,
respectively.
Simulated population evolution. Evolutionary simulations started from a population of 100
identical individuals (parameter sets) derived from a single uniformly sampled parameter point with
normal glucose uptake phenotype. To mutate individuals in this population, that is, to randomize
individual parameters, I performed the following procedure for each of the population’s individuals. I
chose a random one among the 15 parameters and randomized it, that is, I replaced it by a random variate
10x, where x has a uniform distribution on the interval (−3, 3). Subsequently, I computed the glucose
uptake phenotype of the mutated individual. To select from this population of mutated individuals a
new population of equal size in which every member has a normal glucose uptake phenotype (U > U+),
I chose at random (with replacement) individuals from the mutated population, and placed them in
the new population if they had a normal glucose uptake phenotype, until I had filled the population
with N = 100 individuals. I repeated this cycle of mutation and selection 500 times, and computed the
sensitivity coefficient S of each parameter every generation, thus yielding a time series for S, S(t), in the
evolving population. From this time series, I computed the autocorrelation (serial correlation) function
ρ(τ) = cov(S(t), S(t− τ))/var(S(t)), where cov and var indicate covariance and variance, respectively.
Results
Viable parameters comprise a large fraction of parameter space. The model of core insulin
signaling I build on reproduces experimental data, such as insulin receptor dynamics, signaling complex
dynamics, and glucose uptake in rat adipocytes [15, 71]. Its input signal (Figure 1a) is insulin-bound
insulin-receptor that is formed in response to a 100 nM insulin pulse of 15 minute duration (Figure 1b).
The receptor interacts with the protein IRS1 (insulin receptor substrate-1) which becomes tyrosine-
phosphorylated. Phosphorylated IRS1 interacts with phosphoinositide 3-kinase (PI3K) to release
phosphatidylinositol (3,4,5)-triphosphate (PI345P2), which activates the protein kinases C-ζ (PKCZ)
and Akt (Figure 1a, see Methods). The latter two molecules regulate the translocation of the glucose
transporter GLUT4 from intracellular compartments (GLUT4int) to the plasma membrane (GLUT4mem),
where it facilitates glucose import.
Thirteen of the model’s 15 parameters describe the rates of mass-action reactions between signaling
molecules, and the remaining two (fAktP and fPKCZP ) describe the strength of two feedback loops in the
circuit (see Methods and Figure 1a). The primary circuit output is the concentration change of GLUT4mem
whose time integral over 60 minutes I use as a proxy of glucose uptake (Figure 1c). To distinguish normal
circuit output (phenotype) from the pathological phenotype associated with insulin-resistance, I take
advantage of the observation that insulin-resistant mice with impaired glucose-import show a ≈ 70%
reduction in glucose uptake into adipocytes after stimulation with 100 nM insulin [59] (see Methods).
I allowed each of the 15 parameters to range over six orders of magnitude (10−3 < p < 103) and
explored the 15-dimensional parameter space through ‘brute-force’ uniform sampling in the logarithmic
domain (see Methods). From a sample of 9.31 × 105 parameter sets, I computed a viable volume for
the normal glucose uptake phenotype of Vn = 0.076 ± 2.7 × 10−4, expressed as a fractional volume of
parameter space. (The error term reflects the standard deviation of the volume estimate, based on a
normal approximation.) This fractional volume is remarkably high, but not unusually so among other
robust circuits [20, 29]. If along each axis of parameter space the same fraction p of randomly chosen
parameters gave rise to a viable parameter point, the viable volume Vn would be given by Vn = p
15, and
thus p = lnVn/15 ≈ 0.84. In other words, some 84 percent of randomly chosen values for each single
parameter could yield a normal glucose uptake phenotype (depending on the values of other parameters).
The same sampling procedure yields a fractional volume Vd = 0.33± 4.9× 10−4 for the pathological
phenotype of reduced glucose uptake (9.31× 105 sampled points). Because Vd/Vn ≈ 4.4, it is four times
9more likely that a randomly chosen parameter set yields a disease phenotype than a normal phenotype.
Not surprisingly then p = lnVd/15 ≈ 0.93 is also greater than for normal glucose uptake, meaning that 93
percent of randomly chosen values for any one parameter yield a disease state.
Parameters associated with normal or impaired glucose uptake have broad and overlap-
ping ranges. Computing the fraction p of randomly chosen parameters that yield a specific phenotype
tacitly assumes that different parameters can assume broad ranges of values. This assumption may be
violated if parameters critical for signaling behavior are confined to a narrow interval of parameter space.
This is not the case, as Figures 2 and S1. Most parameters can assume very broad ranges of values,
both for normal (blue) and reduced (red) glucose uptake. For example, the distributions of 6 parameters
(blue in Figure 2a-c and m-o) are flat and almost uniform over six orders of magnitude, meaning that
all values for the respective parameters are similarly likely to display a specific signaling behavior. Even
parameters with evident preferences for some values are not strongly constrained. The most narrowly
distributed parameters are kB,PI45P2 (Figure 2f, blue), which promotes the deactivation of the signaling
molecule PIP345P3; and kB,PKCZP (Figure 2l), which accelerates dephosphorylation of protein kinase
C-ζ (Figure 1a). Their probability distributions are somewhat concentrated over four instead of six orders
of magnitude, but even they are not equal to zero outside this parameter range. For example, in some
parameter sets that yield normal signaling behavior, these parameters assume their lowest possible value
of 10−3. Figure S1 further underscores the breadth of these distributions.
As remarkable as these broad distributions are the modest differences between them for normal (blue)
and reduced (red) insulin signaling. If parameters exist where particular values are crucial to determine
glucose uptake, one might expect them to show non-overlapping distributions. However, the distributions
of all parameters overlap widely (Figures 2 and S1), and the distributions of six parameters are almost
congruent (blue and red in Figure 2a-c and m-o). The most distinct distribution pairs indicate weak
preferences for some parameter ranges over others. For example, the parameter kF,PKCZP which promotes
phosphorylation of protein kinase C-ζ tends to have higher values in circuits with normal signaling behavior
(Figure 2j). This is not surprising, given that phosphorylated protein kinase C-ζ promotes membrane
translocation of the glucose transporter. Less easily explained is the observation that the parameter for
the reverse reaction, kB,PKCZ does not show preferentially low but intermediate values in normal signaling
circuits (Figure 2l, blue), and only a weak preference for high values in circuits with reduced signaling
(Figure 2l, red). Similarly, the parameter kB,PI45P2 for the reaction inactivating the signaling molecule
PI345P2 does not show low but intermediate values in normal insulin signaling (Figure 2f, blue), and
only a weak preference for high values – which promote reduced glucose uptake – in circuits with the
pathological phenotype (Figure 2f, red).
In sum, the values of individual parameters associated with normal or reduced glucose signaling
behavior show very broad and broadly overlapping distributions, indicating no obvious ’choke-points’ that
are generic circuit properties independent of any one parameter set. In the supplementary online material
I show that pairwise statistical associations among viable parameters are weak (Figure S2). Moreover, a
principal component analysis shows that no linear combination of parameters can explain most parameter
viability, either for normal or for impaired signaling (Figure S3).
The importance of any one parameter varies by orders of magnitude among viable pa-
rameter sets. The parameter(s) in which change is most likely to alter the signaling phenotype are good
candidates for genetic determinants of disease. To identify these parameters I used two complementary ap-
proaches. In the first I estimated sensitivity coefficients S, which indicate by how much the glucose uptake
rate phenotype U changes (∆U) when a parameter p is changed by a small amount (∆p). Specifically,
S =
∆U/U
∆p/p
(16)
Note that S is dimensionless, because the numerator and the denominator of this quantity express the
amount of change as a ratio, i.e., relative to the current values of U and p. A value of S = 1 indicates that
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a small change in a parameter’s value will cause an equal amount of change in glucose uptake relative to
its current value. For brevity, I will also refer to S as the importance of the parameter p for the phenotype.
I computed sensitivity coefficients for all 15 parameters in each of 1000 uniformly sampled parameter
sets that yield normal circuit behavior. The same parameter can vary dramatically in its importance,
depending on the viable parameter set that it is a part of. Figure 3 indicates the distribution of sensitivity
coefficients (horizontal axis) for each of the 15 model parameters, based on 50 different uniformly sampled
parameter sets. Each vertical bar indicates the sensitivity of the phenotype to a small parameter change.
Note the logarithmic horizontal axis, which shows that any one parameter can vary in its impact on the
phenotype by several orders of magnitude. (I note parenthetically that the signaling circuit also shows
sloppy control [22], i.e., different parameters in the same parameter set also vary in their importance
(Figure S4).)
The full sample of 1000 parameter sets demonstrates the very broad range of S, which spans more
than five orders of magnitude for all parameters, and more than ten for several parameters, such as
kF,IRS1P.PI3K (Figure S5 and Figure S6). Any given parameter may have close to the maximal influence
on glucose uptake for one parameter set (|S| ≈ 0.5), and a negligible influence (S ≈ 10−5 − 10−10) in
some other parameter set (Figure S6).
Next I asked how the importance of the parameters changes relative to one another among different
parameter sets. To this end, I ranked the parameters according to the magnitude of the absolute value of
S for each parameter set. The most important parameter (that with the largest sensitivity coefficient
S) received rank one and that with the smallest S received rank 15. I then analyzed the distribution of
these ranks across all 1000 uniformly sampled parameter set. This distribution is very broad (Figure
4). Specifically, for all but two of the 15 parameters, the distribution spans the entire range from 1 to
15. That is, any one of these parameters is the most important (it has the greatest effect on glucose
uptake) for some parameter set, the least important in some other parameter set, and it has intermediate
importance in others. The ranks of the remaining two parameters kF,IRS1P.PI3K and kB,IRS1SP (Figure
4c and Figure 4o) range from 2 to 15 and from 3 to 15, respectively. That is, they are at best the second-
and third-most important parameters in the circuit. One might think that parameters with a nearly
uniform distribution in the viable set (e.g., kF,PI45P2 in Figure 2e) may be of less overall importance than
parameters with a more sharply peaked distribution, because they are about equally likely to assume any
one value. However, even such parameters can have rank one (Figure 4e).
Every parameter also varies broadly in its propensity to cause deleterious phenotypic
change when mutated. Sensitivity coefficients are calculated from small parameter changes, but DNA
mutations may cause much large changes in the parameters of a biochemical system. I next asked whether
the effects of larger parameter changes are as variable as sensitivity coefficients. To this end, I repeated
the following procedure 100 times for each of the 15 parameters p in each of 1000 uniformly sampled
parameter sets that yield normal glucose signaling: I randomized (‘mutated’) p by assigning to it a
randomly chosen new value that was uniformly distributed along the sampling interval (10−3, 103), and
computed the resulting glucose uptake phenotype. If the change led to glucose uptake below the disease
threshold, I called the change deleterious. (Figure S7 illustrates that the majority of mutations cause
small changes in glucose uptake.) From this data, I computed the fraction fdel of deleterious mutations in
each parameter. For each parameter and across the 1000 parameter sets, fdel shows a highly significant
correlation to S, but one that is only modest in value for some parameters (Spearman’s R=0.16-0.76,
P < 1.7× 10−7, n = 1000 for all parameters), illustrating that S cannot generally substitute as a measure
of fdel. The distribution of fdel shows two commonalities across all parameters. First, in the vast majority
of parameter sets, none of the 100 mutations in any one parameter have a deleterious effect on glucose
uptake, a reflection of the robustness of this signaling circuit (Figure S8). Second, for any one parameter
fdel strongly depends on the parameter set and ranges from zero to more than one half (more than 50
percent of mutations are deleterious, Figure S8). Similarly, a parameter’s rank in its propensity fdel to
suffer deleterious mutations varies broadly across parameter sets (Supplementary Results, Figure S9).
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In sum, the impact on phenotype of small (S) and large (fdel) parameter changes shows similar
patterns. No one determinant of glucose uptake phenotype is consistently more important than others.
Its importance crucially depends on the genetic background one considers.
Logistic and linear regression analysis also demonstrate shifting importance of parame-
ters. Identification of genetic disease determinants often relies on case-control studies, in which many
individuals that are healthy (controls) or affected by a disease (cases) are genotyped genome-wide, and
genes or genetic markers associated with the disease are identified with statistical methods. A frequently
used such method is logistic regression, a generalization of linear regression suitable to analyze data from
case-control studies, because it uses binary dependent variables (afflicted/normal phenotype). The logistic
regression coefficient βi of any one candidate predictor variable li (such as a nucleotide polymorphism)
on disease state can be interpreted as follows: A one unit increase in the predictor variable li alters the
logarithm of the odds-ratio of getting a disease by βi [72]. Predictor variables with larger βi thus alter
the odds-ratio to a greater extent and are thus more important in this sense. Statistical tests that ask
whether βi is significantly different from zero can be used as a measure of importance through the p-value
they generate, because predictors with larger |βi| will usually have a smaller (more significant) p-value. A
parameter with smaller p-value is more important in this sense.
I performed logistic regression on the glucose uptake phenotype, using a binary classification of this
phenotype to distinguish ‘cases’ and ‘controls’ (see Methods). The predictor variables in this analysis
were the insulin signaling circuit’s parameters, which are the closest proxies for genetic determinants in a
mechanistic model. Because case-control studies are usually performed on individuals that are related by
common ancestry in complex ways, the uniformly sampled parameter sets I used in previous analyses
would not be appropriate for this analysis. Instead, I started from a single, ’ancestral’ parameter set and
created from it a ‘population’ of related parameter sets (individuals) whose glucose uptake was either
normal (1000 individuals) or reduced below the disease threshold (another 1000 individuals, see Methods).
I repeated this procedure 100 times, thus creating 100 pairs of case-control populations, and asked how
strongly the importance of individual parameters, as represented through the p-value of their logistic
regression coefficient, varied among them.
The importance of individual parameters varies enormously (Figure S10). Even in the parameter with
the least variable importance, as indicated by −log10p (fPKCZP ; Figure S10n), −log10p varies over 47
orders of magnitude between p = 1.8× 10−48 to p = 0.93. In the most variable parameter (kF,PKCZP , the
value of −log10p varies over 98 orders of magnitude. And while every parameter is very important (has low
p-value) in some parameter sets, it is completely unimportant in others. The percentage of populations
where p > 0.05 ranges from 48 percent for kB,IRS1SP (Figure S10o) to 1 percent for kB,PI45P2 (Figure
S10f), with a mean of 24.5 percent among parameters. In other words in an average of one quarter of all
populations, any one parameter has no statistically detectable importance to the phenotype, even though
it may be the most important determinant of phenotype in other populations. The shifting importance
of parameters is also illustrated by the distribution of ranks among the p-values, which I computed
analogously to similar analyses above. Specifically, for each parameter set in each of the 100 population
pairs, I assigned the parameter with the smallest (most significant) p-value the highest rank of 1, and
that with the largest p-value the lowest rank of 15 (Figure 5). The distribution of ranked importance
is broad and spans all 15 possible ranks for 12 of the 15 parameters. Any of these 12 parameters is the
most important in some populations but the least important in others. The ranks of the remaining three
parameters range from 15 to 3 (kB,IRS1P.PI3K , Figure 5d), 4 (fPKCZP , Figure 5n), and 2 (kB,IRS1SP ,
Figure 5o). That is, these parameters are not the most important in any population.
Logistic regression analysis can identify genetic disease determinants when only qualitative phenotypic
information (normal/diseased) is available. However, whenever quantitative information is available, such
as in the form of glucose uptake rate values, linear regression analysis is preferable, because it uses all
available phenotypic information. I thus repeated the preceding analysis of p-values derived from logistic
regression, but for p-values derived from linear regression analysis of the 15 parameters against the glucose
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uptake phenotype, with very similar results (Supplementary Results, Figure S11 and S12). Briefly, the
importance of most parameters for the phenotype varies broadly, from least to most important. Linear
regression analysis also demonstrates that in most populations, the majority of phenotypic variance is
accounted for by additive interactions among parameters (R2 > 0.5, Figure S13a), and that the role of
pairwise epistasis is minor (Supplementary Results, Figure S13b and c). However, both observations
illustrate how linear regression can mislead, because of the broad variability of parameter importance.
The relative importance of predictor variables (parameters) in a truly linear model would be essentially
the same in different populations of the size I study, but this is emphatically not the case in the insulin
signaling circuit, where a parameter may have a very high importance in some populations and very low
importance in others.
Parameter importance fluctuates rapidly in time. The observations I made so far do not reveal
how fast parameter importance would change in an evolving population that is subject to mutations
randomizing parameters and stabilizing selection maintaining normal glucose uptake. To find out,
I subjected populations of N = 100 individuals (parameter sets) to 500 rounds or ‘generations’ of
‘mutation’(one randomized parameter per generation and individual) followed by stringent selection for
normal glucose uptake (see Methods). During this simulation, I computed the sensitivity coefficient S
for all parameters in every generation. Figure 6a shows as an example the resulting data for parameter
kB,PI34P2. The parameter’s importance (|S|) does not stay constant for long, but fluctuates rapidly and
broadly, i.e., by more than thousand-fold (Note the logarithmic vertical scale). Figure 6b shows that the
rank of |S| for this parameter also changes repeatedly and rapidly from a minimum of 15 (least important)
to a maximum of four (fourth-most important). Thus, while the parameter does not explore its full range
of importance (1-15, Figures 4h) during this short time, its importance varies broadly.
A commonly used measure for the rate of fluctuation in time-series like this is the autocorrelation
function ρ(τ) of a quantity of interest (here, the sensitivity coefficient S(t)) at time t and time t− τ (see
Methods). This function indicates to what extent S(t) assumes similar values τ generations apart. Figure
6c shows ρ(τ) of S(t) for parameter kB,PI34P2 as a function of the time lag τ . Even for the smallest time
lag τ = 1 considered, ρ(τ) ≈ 0.6, far below the theoretically possible maximum of one. In other words,
this parameter changes its importance even at the smallest time lag considered here. Moreover, the decay
time of the autocorrelation function, that is, the time needed until ρ(τ) first decreases below one half
of its maximal value at ρ(1) is only τ = 4 generations. Figure 6d shows a histogram of this decay time
for all 15 parameters. It ranges between 4 and 18 generations, with a mean of 7 generations. In sum, in
simulated evolving populations of individuals, the importance of individual parameters can change rapidly
on an evolutionary time scale.
Discussion
I computed four complementary measures of how changes in genetically encoded biochemical parameters
would impact the glucose uptake phenotype of the insulin signaling pathway. The first of them is the
sensitivity coefficient – the amount of phenotypic change caused by a small parameter change. The second
is the fraction of random mutations in a parameter that causes deleterious phenotypic change. The third
is based on a multiple logistic regression of all parameters against the phenotype. It is the p-value of a
test of the null-hypothesis that a parameter’s regression coefficient on the phenotype is equal to zero. The
fourth is the same as the third, but for multiple linear regression.
All four measures yield the same observation when applied to different and uniformly sampled viable
parameter sets that yield normal glucose uptake: Genetic determinants of the phenotype vary broadly in
their impact on this phenotype. A parameter that is crucial for the phenotype in one genotypic background
– it has the highest sensitivity, the largest fraction of deleterious mutations, or the most significant (lowest)
p-value in regression – will be unimportant in other backgrounds. When ranking parameters according
to their importance from one (most important) to fifteen (least important), most parameters assume
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all ranks in some genetic backgrounds. Those that do not are usually not the most important in any
background.
Parameter sensitivity and mutational effects gauge how a system’s phenotype reacts to perturbation,
which is the most reliable way to identify the causes of a system’s phenotype. Together, they show
that in a system like that studied here, any polymorphism that is truly causal in one population or
genetic background may be acausal in another. Robust systems can diverge genetically without diverging
phenotypically, and such divergence can lead to causal drift – shifting patterns of causality among system
components. For a robust system like this, no universally useful choke points exist that could serve to
control circuit behavior. I note that there are many biological systems [19–22,29–31] whose robustness is
similar to that of the insulin signaling circuit.
One may question the usefulness of linear regression to analyze an obviously highly nonlinear relationship
between circuit parameters and phenotype. My primary motivation to use regression is that it is very
common in genome-wide association studies [73]. Its results thus help compare the statistical and
mechanistic approach, and they can illustrate how the statistical approach can mislead. In most of
the 100 populations I studied, the proportion of phenotypic variation explained by linear regression
exceeds 50 percent. The facile conclusion would be that additive interactions among genetic determinants
predominate in the insulin circuit. However, a comparison of different populations reveals how variable a
parameter’s impact on phenotype can be: Its p-value can be non-significant (p > 0.05) in one population,
yet the most significant among all parameters (e.g., p < 10−100) in another. Because of the large sample
sizes considered here (1000 individuals per population) the estimated regression coefficients and associated
p-values under true additivity would be virtually identical across populations. In reality they differ wildly,
meaning that regression analysis only creates the appearance of additivity. True additivity cannot give
rise to the causal drift I observe.
Causal drift is clearly a result of non-additive (epistatic) interactions among parameters. In this regard,
it is noteworthy that pairwise epistasis between parameters may not suffice to explain the extent of causal
drift, because such epistasis explains little phenotypic variation (FigureS13). This observation hints at an
important role for higher order epistasis, i.e., for interactions among three or more genetic determinants.
Moreover, it also hints at a possible limitation of quantitative genetic studies that fail to detect pairwise
epistasis for a given phenotype and population. Explaining phenotypic variation might require higher
order epistasis, which is difficult to detect with statistical methods, because of the large number of possible
interactions among three or more variates. In addition, it is possible that causal drift shifts patterns of
epistasis among populations, just as it shifts the causal influence of individual parameters. In this case,
parameters that interact epistatically in one population may lack such interactions in another, such that
even combinations of genetic determinants may not suffice to explain a phenotype reliably and across
populations.
Mechanistic models like the one I analyze have one obvious limitation. They represent genetic disease
determinants through biochemical parameters, and not directly on the level of DNA. However, this
limitation is also matched by advantages. First, a mechanistic model can provide insights into disease
causes that go beyond statistical associations. Second, factors that can complicate the interpretation of
genome-wide association studies, such as recessiveness, linkage disequilibrium, environmental change, and
population stratification, play no role here. Third, sample sizes are arbitrarily large, such that lack of
statistical power is no limitation. Fourth, because the model is deterministic, the influence of every single
variable on the phenotype can be made transparent. The mechanistic approach can show that causal drift
is a consequence of the system’s genetic architecture, and not an artefact of limited information about the
relevant variables.
Because the model I study here is simple, it is important to note opportunities for causal drift would
be even greater in more complex models. For example, the model I consider does not include synthesis
and decay rates of individual circuit proteins. In a model incorporating either, the phenotypic effect
of a mutation that reduces the rate k at which two proteins A and B bind could be neutralized by an
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increase in the synthesis rate or a decrease in the degradation rate of either. The reason is that under
mass-action, the rate at which A and B bind is a function of the concentration of both molecules and
the rate constant k, e.g., k[A][B] in its simplest form. Similarly, the model I consider does not consider
signaling components that may be encoded by duplicate genes, such as the insulin receptor substrate IRS1
with its duplicate IRS2 [74,75]. Here again, changes in one duplicate that increase its concentration or
activity could be compensated by opposing changes in the other. More generally, every additional state
variable and interaction provides more opportunities for causal drift.
A central observation of this analysis – that a biochemical circuits parameters can vary in their
importance – could be influenced by additional constraints on a circuit or its parts. For example, the same
biochemical circuit may need to operate under different conditions in different tissues, or some molecules in
a circuit may be involved in cross-talk to other circuits, constraining the biochemical parameters that permit
such cross-talk. Previous work suggests that such additional constraints would have to be very extreme to
affect my observations. For example, in each of 17 different biological circuits, constraining phenotypes
by requiring that a circuit’s phenotype fit 100 times more (simulated) concentration measurements than
parameters yielded similar variation in the importance of biochemical parameters than that observed
here [22]. The varying importance of parameters is a general property of circuit architecture rather than of
a specific set of parameters or constraints [22, 35, 76]. In addition, experimental evidence shows that even
biological circuits with highly constrained phenotypes can change their architecture. For example, in the
circuits controlling galactose metabolism, mating, and ribosomal gene expression of yeast [77–79], the same
phenotype can be produced by circuits in which both biochemical parameters and circuit topology vary
widely. Another particularly well-studied example comes from the reproductive organs of the nematode
worm C. elegans, and specifically from the development of its vulva. Different worm species produce
morphologically identical adult vulvae but do so through developmental pathways that differ on every level
of organization, from the identity and interactions of signaling molecules, to the communication processes
between cells in the developing organ [80–85]. It is the flexibility of biological circuits in achieving the
same ends by different means that permits the genetic changes responsible for causal drift.
Although we cannot currently estimate the rate at which parameters of biochemical circuits change
in human evolution, it is clear that the human population contains ample genetic polymorphisms that
affect such parameters. A case in point are genetic polymorphisms in the insulin signaling pathway with
demonstrable effects on diabetes and other diseases. For example, a glycine to arginine change in IRS1
(G972R) causes a reduction in the ability of IRS1 to interact with PI3K, as well as in the activity of
PI3K [39]. The polymorphism occurs naturally in the human population and is associated with variation
among individuals in insulin secretion, and insulin resistance [40–43,86]. It also affects birth weight in a
Brazilian population [87], in line with known effects of insulin signaling on growth phenotypes [88, 89].
In addition, it affects the incidence of polycystic ovary syndrome among Japanese individuals [90] and
the risk of colorectal cancer in a Czech population [91]. Similarly, an amino acid change (M326I) in
the p85 subunit of PI3K affects glucose tolerance [41]. Naturally occurring polymorphisms in PI3K,
Akt, and IRS2 affect risk for coronary artery disease, metastatic lung cancer, and survival in esophagal
cancer [92–94]. Moreover, some such effects depend on the population studied. A G1057D polymorphism
in IRS2 is associated with diabetes risk in Han Chinese [44], but not with insulin resistance or secretion
in a Finnish population [95].
Other experimental evidence also suggests that causal drift exists in the human population. For
example, it has long been known that the detrimental effect of a given mutation in a ‘disease-causing’ gene
depends strongly on an individual’s genetic background. This holds even for ‘monogenic’ diseases like
thalassaemias and phenylketonuria [96,97]. Genome sequencing has multiplied information about such
background effects on disease and drug efficacy, which can even occur within a single family [98]. The
increasing importance of personalized medicine and pharmacogenomics [98, 99] underscore the prevalence
of such background effects. And if causal drift exists in the human population with its recent common
ancestry, it is likely to play an even greater role on the time scales that separate humans from model
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organisms like mice. If so, caution will be necessary when transferring information about biological circuits
from model organisms to understand human disease.
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Figure 1. Insulin signaling model, input and output. a) Molecular interactions in the signaling
pathway modeled here. Briefly, extracellular insulin leads to phosphorylation of the insulin receptor,
which promotes the phosphorylation of IRS1 to yield IRS1P . The latter molecule associates with PI3K
in a complex that triggers production of the second messenger PI345P3, which activates the protein
kinases Akt and PKCZ. These kinases then promote the translocation of the glucose transporter
GLUT4 to the membrane, where it helps import glucose into the cell. Mass-action parameters that
determine the rates of the respective reactions are indicated by a ‘k’ followed by a subscript. Activated
PKCZ and Akt exert feedback on the production of two different phosphorylated forms of IRS1
(IRS1SP and IRS1P ). The strength of this feedback is encapsulated by parameters fPKCZP and fAktP ,
respectively. See Methods for details. b) The temporal dynamics of the input signal (vertical axis), which
consists of phosphorylated insulin receptor in response to a 15 minute long insulin pulse. This signal
promotes the production of IRS1P (see equation 2). c) Signaling output, represented as a histogram of
the distribution of glucose uptake in arbitrary units (a.u.) within a 60 minute interval after the insulin
pulse. Blue and red histograms are based on 100 randomly sampled parameter sets that lead to glucose
uptake rates characteristics for normal (blue) and diseased, insulin resistant cells (red), based on observed
glucose uptake in mouse adipocytes [59]. The inset shows the concentration of membrane-bound GLUT4
as a function of time, for the same two randomly sampled parameter sets.
Figure 2. Distribution of randomly sampled parameters that yield normal and diseased
signaling behavior. Each panel shows, on a logarithmic horizontal scale, the distribution of parameter
values p ∈ (10−3, 103) that yield normal (blue) or reduced (red) glucose uptake. Each data set in each
panel is based on 2× 105 parameter sets sampled uniformly from the viable region of parameter space for
the two phenotypes.
Figure Legends
Figure 3. The importance of the same parameter can vary widely across different
parameters sets. The horizontal axis indicates the log-transformed absolute value of sensitivity
coefficients S. Each horizontal row contains 50 black vertical bars, which correspond to the sensitivity
coefficient S of one parameter (labeled on the vertical axis) for 50 different parameter sets uniformly and
randomly sampled from the region of parameter space yielding a normal glucose uptake phenotype. Note
that each parameter’s sensitivity coefficient S varies over multiple orders of magnitude.
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Figure 4. A parameter’s importance depends strongly on the parameter set. The data is
based on sensitivity coefficients of all parameters in each of 1000 uniformly sampled parameter sets that
yield a normal glucose uptake phenotype. For each of the 1000 viable parameter sets, I ranked parameters
according to the magnitude of the absolute value of their sensitivity coefficient, from rank one (largest
|S|) to rank 15 (smallest |S|). Each panel shows, for the parameter indicated on top, a histogram of the
distribution of these ranks among the 1000 parameter sets. The vertical axis is drawn on a linear scale.
Note the broad distribution of parameter ranks, implying that a parameter’s importance can vary broadly
among parameter sets.
Figure 5. Logistic regression shows that a parameter’s importance for the disease
phenotype can vary broadly among populations. Each panel shows a histogram of the rank of p
for the parameter indicated on top, where p is the p-value of the parameter’s regression coefficient in a
logistic regression against individuals with normal (‘control’) and impaired (‘case’) glucose uptake
phenotype. For each parameter set, the parameters were ranked according to the magnitude of p, such
that the parameter with the smallest p (most significant parameter) received the highest possible rank of
one, and that with the largest p received the lowest possible rank of 15. The vertical axis is drawn on a
linear scale. Note that the ranks have a broad distribution for all parameters, indicating that parameters
that are important in some individuals are unimportant in others. Data are based on 100 pairs of
populations (parameter sets) that showed either normal or reduced glucose uptake. Each population was
derived from a single individual with normal glucose uptake and comprised 1000 individuals each (See
methods for details). Control and case phenotypes are binarily encoded as one and zero, respectively.
Figure 6. In evolving populations parameters can fluctuate rapidly in their importance. a)
Temporal change of the sensitivity coefficient (|S|) for the parameter kB,PI34P2 during 500 generations of
simulated evolution in a population of N = 100 individuals (see Methods). Note the logarithmic vertical
scale and the rapid fluctuations. b) like a), but for the rank that |S| of kB,PI34P2 has among all 15
parameters. c) shows the autocorrelation function of log|S| (vertical axis) as a function of the lag τ (see
Methods), calculated over 500 generations of simulated evolution. d) histogram of decay time for the
autocorrelation function of all 15 parameters. The shortest possible decay time given the sampling
interval of one generation for the computation of |S| is τ = 2.
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Supporting Information
S1 Fig
Box plot of randomly sampled parameters that yield normal and impaired signaling behav-
ior. The two box plots next to each parameter name reflect the parameter values that yield normal (’N’,
blue) and reduced (’D’ for diseased, red) glucose uptake. The horizontal axis (logarithmic scale) covers
the admissible parameter range (10−3, 103). The box lot for each parameter is based on 2× 105 parameter
sets sampled uniformly from a viable region of parameter space (both for normal and reduced glucose
uptake). Circles indicate medians, boxes indicate the 25th percentile, q25, and the 75th percentile, q75.
Whiskers span the interval (q25 − 1.5(q75 − q25), q75 + 1.5(q75 − q25)) corresponding to approximately 99.3
percent coverage of normally distributed data.
S2 Fig
Pairwise associations among model parameters. Each data point shows Spearman’s rank correlation
coefficient for a pair of parameters, both for normal glucose signaling (horizontal axis) and reduced glucose
signaling (vertical axis). Note the axes scales, which extend only to the half-maximal possible values for
R. Data are based on 1000 pairs of parameter sets sampled uniformly from the region of parameter space
associated with normal or reduced glucose signaling.
S3 Fig
Principal component analysis. Data are based on 1000 uniformly sampled parameter sets that yield
normal (panels a) and b)) or reduced (c) and d)) signaling behavior. Panels a) and c) show the fraction
of the variance explained by each of the 15 principal components (horizontal axis) of the 15-dimensional
parameter space. Panels b) and d) show the first two principal components plotted against one another.
S4 Fig
Sensitivity coefficients vary widely among parameters across multiple parameter set. The
horizontal axis indicates the log-transformed absolute value of sensitivity coefficients S. The plot has 50
horizontal rows of short vertical bars. Each row corresponds to a different parameter set uniformly and
randomly sampled from the viable region of parameter space yielding a normal glucose uptake phenotype.
Each row has 15 vertical bars, which indicate the value of S for each of the 15 parameters in the parameter
set (For rows where this number of bars appears lower, two or more parameters have values of S that
are so similar that some individual bars cannot be resolved). Note that the different parameters have
sensitivity coefficients S that vary over multiple orders of magnitude.
S5 Fig
Sensitivity of phenotype to perturbation of a given parameter varies broadly among viable
parameter sets. Each panel shows the distribution of sensitivity coefficients for the parameter indicated
on top, based on 1000 randomly and uniformly distributed parameter sets that yield a glucose uptake
phenotype. Note the logarithmic vertical axis.
S6 Fig
Sensitivity of phenotype to parameter perturbation varies broadly among viable parameter
sets. Each panel shows the distribution of log|S|, the decadic logarithm of the absolute value of sensitivity
coefficients for the parameter indicated on top. Data is based on 1000 randomly and uniformly distributed
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parameter sets that yield normal glucose uptake. The vertical axis is drawn on a linear scale. Note the
broad distribution of S, which spans multiple orders of magnitude.
S7 Fig
Quantitative effects of random parameter changes on glucose uptake. The panel shows the
distribution of the absolute value of the relative change in glucose uptake |∆U/Uwt|=|(Umut − Uwt)/Uwt|,
where Uwt is the glucose uptake value associated with a randomly sampled viable parameter set, i.e., a set
with normal glucose uptake, and Umut is the glucose uptake value that results if one randomly chosen
parameter within this set is randomized, i.e., assigned a new value 10x, where x is a uniform random
variate in the interval (−3, 3). The data in the figure is based on 5000 such randomly sampled viable
parameter sets. Note the logarithmic scale on the horizontal axis. The data shows that the majority of
changes are modest in quantity (log10|∆U/Uwt| ≤ 0).
S8 Fig
A parameter’s likelihood fdel to cause deleterious effects when mutated varies broadly across
viable parameter sets. Each panel shows the distribution of fdel, the fraction of deleterious mutations,
for the parameter indicated on top. Note the logarithmic vertical scale. Data is based on 1000 randomly
and uniformly distributed parameter sets that yield normal glucose uptake. Note that fdel = 0 for most
parameter sets, and that fdel shows a broad distribution.
S9 Fig
A parameter’s likelihood fdel to cause deleterious effects when mutated varies broadly across
viable parameter sets. For the data in this figure, I first computed fractions of deleterious mutations
fdel for all parameters in each of 1000 parameter sets uniformly and randomly sampled from the region
of parameter space yielding a normal glucose uptake phenotype. For each parameter set, I then ranked
the parameters according to the magnitude of fdel. The parameter with the largest fdel received rank
one, and all parameters with the smallest possible fdel = 0 received the lowest possible rank of 15. Each
panel shows, for the parameter indicated on top, a histogram of the distribution of these ranks among the
1000 parameter sets. Note the logarithmic vertical scale, and that each parameter has the lowest possible
rank in the vast majority of the 1000 parameter sets. Nonetheless, each parameter is important (has rank
equal or close to one) for a normal glucose-uptake phenotype in some viable parameter sets.
S10 Fig
Logistic regression shows that a parameter’s importance for the disease phenotype can vary
broadly among populations. Each panel shows a histogram of −log10p for the parameter indicated
on top, where p is the p-value of the parameter’s regression coefficient in a logistic regression against
individuals with normal (‘control’) and impaired (‘case’) glucose uptake. The vertical axis is drawn on a
linear scale. Note that the p-values vary among many orders of magnitude. Data are based on 100 pairs
of populations (parameter sets) that showed either normal or reduced glucose uptake. Each population
pair was derived from a single individual with normal glucose uptake and comprised 2000 individuals (See
methods for details). Control and case phenotypes are binarily encoded as one and zero, respectively.
S11 Fig
Linear regression shows that a parameter’s importance for the disease phenotype can vary
broadly among populations. Each panel shows a histogram of −log10p for the parameter indicated
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on top, where p is the p-value of the linear regression coefficient of the parameter against the continuously
valued glucose uptake phenotype (equation 15). The vertical axis is drawn on a linear scale. Note that
the p-values vary among many orders of magnitude. As in the logistic regression analysis, data are
based on 100 pairs of populations (parameter sets) that showed either normal or reduced glucose uptake.
Each population was derived from a single individual with normal glucose uptake and comprised 1000
individuals (See methods for details).
S12 Fig
Linear regression shows that a parameter’s importance for the disease phenotype can vary
broadly among populations. Each panel shows a histogram of the rank of p for the parameter indicated
on top, where p is the p-value of the linear regression coefficient of the parameter against the glucose
uptake phenotype (equation 15). For each parameter set, I ranked parameters according to the magnitude
of p, such that the parameter with the smallest (most significant) value of p received the highest possible
rank of one, and that with the largest p received the lowest possible rank of 15. The vertical axis is
drawn on a linear scale. Note that the ranks have a broad distribution for all parameters, indicating that
parameters important in some individuals are unimportant in others. As in the logistic regression analysis,
data are based on 100 pairs of populations (parameter sets) that showed either normal or reduced glucose
uptake. Each population was derived from a single individual with normal glucose uptake and comprised
1000 individuals (See methods for details).
S13 Fig
Additive and multiplicative epistatic interactions explain most of the phenotypic variance.
Each panel shows a histogram of the coefficient of determination R2 from a regression of the 15 model
parameters as predictor variables xi against the continuous glucose uptake phenotype (equation 15). a)
linear regression
∑
βixi; b) linear regression with multiplicative interaction terms (
∑
i βixi+
∑
i<j ijxixj);
c) Difference in R2 between the multiplicative and the linear model. As in the logistic regression analysis,
data are based on 100 pairs of populations (parameter sets) that showed either normal or reduced glucose
uptake. Each population was derived from a single individual with normal glucose uptake and comprised
1000 individuals (See methods for details).
S1 Text
Supplementary Results.
S1 Code
Programs to generate data.
27
Figure S1
Figure S2
Figure S3
Figure S4
Figure S5
Figure S6
Figure S7
Figure S8
Figure S9
Figure S10
Figure S11
Figure S12
Figure S13
IRS-1
IRS-1
P
PI3-K
IRS-1
P
PI3-K
PI45P2PI34P2
PI345P3
PKCZ PKCZ
P
Akt Akt
P
IRS-1
SP
+
GLUT4
k
F,IRS1Pk
B,IRS1P
f
AktP
f
PKCZP
k
B,IRS1SP
k
B,IRS1P.PI3K
k
F,IRS1P.PI3K
k
F,PI45P2
k
B,PI34P2
k
B,PI45P2
k
F,PI34P2
k
B,AktP
k
F,AktP
k
B,PKCZP
k
F,PKCZP
0 500 1000 1500 2000 2500 3000 3500 4000 4500
0
10
20
30
40
50
60
70
80
Glucose uptake (a.u.)
N
u
m
b
e
r 
o
f 
p
a
ra
m
e
te
r 
s
e
ts
normal
diseased
0 20 40 60
0
50
100
time (min)
m
e
m
b
ra
n
e
−
b
o
u
n
d
 G
L
U
T
4
 (
%
)
0 10 20 30 40 50 60
0
0.2
0.4
0.6
0.8
1
time (min)
S
IG
N
A
L
 (
n
M
)
)b)a
c)
input signal
Figure 1
Click here to download Figure: Figure1_Signaling_pathway_input_output_v1.eps 
−3 0 3
0
2000
4000
6000
k
F,IRS1P
a) normal
diseased
−3 0 3
0
2000
4000
6000
k
B,IRS1P
b)
−3 0 3
0
2000
4000
6000
k
F,IRS1P.PI3K
c)
−3 0 3
0
2000
4000
6000
k
B,IRS1P.PI3K
d)
−3 0 3
0
2000
4000
6000
k
F,PI45P2
e)
−3 0 3
0
2000
4000
6000
k
B,PI45P2
f)
−3 0 3
0
2000
4000
6000
k
F,PI34P2
g)
−3 0 3
0
2000
4000
6000
k
B,PI34P2
h)
−3 0 3
0
2000
4000
6000
k
F,AKTP
i)
−3 0 3
0
2000
4000
6000
k
F,PKCZP
j)
−3 0 3
0
2000
4000
6000
k
B,AKTP
k)
−3 0 3
0
2000
4000
6000
k
B,PKCZP
l)
−3 0 3
0
2000
4000
6000
f
AktP
m)
−3 0 3
0
2000
4000
6000
f
PKCZP
n)
−3 0 3
0
2000
4000
6000
k
B,IRS1SP
o)
Figure 2
Click here to download Figure: Figure2_PLoS_revised_with_yaxes_labels.eps 
log|S|
−9 −8 −7 −6 −5 −4 −3 −2 −1 0
k
F,IRS1P
k
B,IRS1P
k
F,IRS1P.PI3K
k
B,IRS1P.PI3K
k
F,PI45P2
k
B,PI45P2
k
F,PI34P2
k
B,PI34P2
k
F,AKTP
k
F,PKCZP
k
B,AKTP
k
B,PKCZP
f
AktP
f
PKCZP
k
B,IRS1SP
Figure 3
Click here to download Figure: Figure3_sens_bypara_bar_v1_converted_to_pdf_processed.eps 
1 5 10 15
0
50
100
150
200
a)
k
F IRS1P
rank|S|
1 5 10 15
0
50
100
150 b)
k
B IRS1P
rank|S|
1 5 10 15
0
50
100
150
200
c)
k
F IRS1P PI3K
rank|S|
1 5 10 15
0
50
100
150 d)
k
B IRS1P PI3K
rank|S|
1 5 10 15
0
50
100
150
e)
k
F PI45P2
rank|S|
1 5 10 15
0
100
200
f)
k
B PI45P2
rank|S|
1 5 10 15
0
50
100
150
200 g)
k
F PI34P2
rank|S|
1 5 10 15
0
50
100
150
200 h)
k
B PI34P2
rank|S|
1 5 10 15
0
50
100
150 i)
k
F AKTP
rank|S|
1 5 10 15
0
100
200
300
j)
k
F PKCZP
rank|S|
1 5 10 15
0
50
100
k)
k
B AKTP
rank|S|
1 5 10 15
0
100
200
l)
k
B PKCZP
rank|S|
1 5 10 15
0
50
100
150 m)
f
AktP
rank|S|
1 5 10 15
0
100
200
n)
f
PKCZP
rank|S|
1 5 10 15
0
100
200
300
o)
k
B IRS1SP
rank|S|
Figure 4
Click here to download Figure: Figure4_PLoS_revised_rankS_with_yaxes_labels.eps 
1 5 10 15
0
5
10
15
a)
k
F IRS1P
rank(p)
1 5 10 15
0
5
10
b)
k
B IRS1P
rank(p)
1 5 10 15
0
5
10
15
c)
k
F IRS1P PI3K
rank(p)
1 5 10 15
0
5
10
15
20 d)
k
B IRS1P PI3K
rank(p)
1 5 10 15
0
5
10
15
20
e)
k
F PI45P2
rank(p)
1 5 10 15
0
10
20
30
40 f)
k
B PI45P2
rank(p)
1 5 10 15
0
5
10
15
20 g)
k
F PI34P2
rank(p)
1 5 10 15
0
5
10
15
20
h)
k
B PI34P2
rank(p)
1 5 10 15
0
5
10
15
20
i)
k
F AKTP
rank(p)
1 5 10 15
0
10
20
30
40 j)
k
F PKCZP
rank(p)
1 5 10 15
0
5
10
15 k)
k
B AKTP
rank(p)
1 5 10 15
0
10
20
l)
k
B PKCZP
rank(p)
1 5 10 15
0
5
10
15 m)
f
AktP
rank(p)
1 5 10 15
0
5
10
15
n)
f
PKCZP
rank(p)
1 5 10 15
0
5
10
15
20
o)
k
B IRS1SP
rank(p)
Figure 5
Click here to download Figure: Figure5_PLoS_revised_rankP_logregr_yaxes_labels.eps 
0 100 200 300 400 500
−5
−4
−3
−2
−1
a)
time
lo
g|S
|
0 100 200 300 400 500
2
4
6
8
10
12
14
16
b)
time
ra
n
k|S
|
1 5 10 15 20 25
0
0.2
0.4
0.6
0.8
1
c)
time lag
au
to
co
rr
el
at
io
n 
of
 lo
g|S
|
2 5 10 15
0
2
4
6
8
10
decay time
pa
ra
m
et
er
s
d)
Figure 6
Click here to download Figure: Figure6_pop_drift_sim_v1.eps 
